Pathstone Holdings LLC Has $27.05 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Pathstone Holdings LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 3.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 347,234 shares of the company’s stock after purchasing an additional 11,703 shares during the period. Pathstone Holdings LLC’s holdings in AstraZeneca were worth $27,053,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AZN. Stratos Wealth Advisors LLC lifted its stake in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after purchasing an additional 133 shares during the last quarter. Bruce G. Allen Investments LLC lifted its position in shares of AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after buying an additional 138 shares during the last quarter. Carnegie Investment Counsel boosted its stake in shares of AstraZeneca by 0.8% during the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after acquiring an additional 138 shares in the last quarter. Crumly & Associates Inc. increased its holdings in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after acquiring an additional 143 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after acquiring an additional 146 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AZN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 0.6 %

AZN stock opened at $63.80 on Wednesday. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market cap of $197.82 billion, a PE ratio of 30.53, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The business’s 50-day simple moving average is $74.34 and its 200 day simple moving average is $78.06.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.87 EPS. On average, research analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.